Literature DB >> 16061757

Cyclooxygenase inhibition and cardiovascular risk.

Elliott M Antman1, David DeMets, Joseph Loscalzo.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 16061757     DOI: 10.1161/CIRCULATIONAHA.105.568451

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  57 in total

1.  Helicobacter pylori Infection and Inflammation: Implication for the Pathophysiology of Diabetes and Coronary Heart Disease in Asian Indians.

Authors:  M Afzalur Rahman; Mark B Cope; Shafique A Sarker; W Timothy Garvey; Habib S Chaudhury; Mohammad A Khaled
Journal:  J Life Sci       Date:  2009-07

2.  Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases.

Authors:  Soyoung Kim; Jianwen Cai; David Couper
Journal:  Stat Med       Date:  2015-08-26       Impact factor: 2.373

3.  Life without COX 2 inhibitors: risks and benefits are determined by dose and potency.

Authors:  Enrique J Sánchez-Delgado
Journal:  BMJ       Date:  2006-06-17

Review 4.  Understanding the NSAID related risk of vascular events.

Authors:  Harald E Vonkeman; Jacobus R B J Brouwers; Mart A F J van de Laar
Journal:  BMJ       Date:  2006-04-15

Review 5.  Using recovery modalities between training sessions in elite athletes: does it help?

Authors:  Anthony Barnett
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

6.  The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.

Authors:  D Williams; M Singh; C Hind
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 7.  The big idea: the coxib crisis iron, aspirin and heart disease risk revisited.

Authors:  Jerome L Sullivan
Journal:  J R Soc Med       Date:  2007-07       Impact factor: 5.344

8.  Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  C R Lee; K E North; M S Bray; D J Couper; G Heiss; D C Zeldin
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

9.  Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea.

Authors:  Sanja Jelic; Margherita Padeletti; Steven M Kawut; Christopher Higgins; Stephen M Canfield; Duygu Onat; Paolo C Colombo; Robert C Basner; Phillip Factor; Thierry H LeJemtel
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

10.  Non-steroidal anti-inflammatory drugs attenuate the vascular responses in aging metabolic syndrome rats.

Authors:  María Esther Rubio-Ruiz; Israel Pérez-Torres; Eulises Diaz-Diaz; Natalia Pavón; Verónica Guarner-Lans
Journal:  Acta Pharmacol Sin       Date:  2014-09-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.